Henrique Caracho Ribeiro

Henrique Caracho Ribeiro

Auto-generated profile, based on publicly available information

Henrique Caracho Ribeiro

School of Medical Sciences, Faculty of Medicine and Health, Örebro University, SE-702 81, Örebro, Sweden

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2017
Verified
Book Chapter
Closed access
PDF file
AKAline Klassen
Aline Klassen
AFAndréa Tedesco Faccio
Andréa Tedesco Faccio
Gisele André Baptista CanutoGisele André Baptista Canuto
Gisele André Baptista Canuto
PCPedro Luis Rocha da Cruz
Pedro Luis Rocha da Cruz
HRHenrique Caracho Ribeiro
Henrique Caracho Ribeiro
Alessandra SussuliniAlessandra Sussulini
Alessandra Sussulini

1 December 2017 in Psychiatry Research
Verified
Journal Article
Closed access
HRHenrique C. Ribeiro
Henrique C. Ribeiro
AKAline Klassen
Aline Klassen
MPMariana Pedrini
Mariana Pedrini
MCMichelle S. Carvalho
Michelle S. Carvalho
LRLucas B. Rizzo
Lucas B. Rizzo
Alessandra SussuliniAlessandra Sussulini
Alessandra Sussulini

17 March 2022 in Annals of Neurology
Verified
Journal Article
Open access
BGBruno Ghirotto
Bruno Ghirotto
DODanyllo F. Oliveira
Danyllo F. Oliveira
MCMarcella Cipelli
Marcella Cipelli
PBPaulo J. Basso
Paulo J. Basso
JLJean de Lima
Jean de Lima
NCNiels Olsen Saraiva Camara
Niels Olsen Saraiva Camara
Objective: Astrocytes play a significant role in the pathology of multiple sclerosis (MS). Nevertheless, for ethical reasons, most studies in these cells were performed using the Experimental Autoimmune Encephalomyelitis model. As there are significant differences between human and mouse cells, we aimed here to better characterize astrocytes from patients with MS (PwMS), focusing mainly on mitochondrial function and cell metabolism.Methods: We obtained and characterized induced pluripotent stem cell (iPSC)‐derived astrocytes from three PwMS and three unaffected controls, and performed electron microscopy, flow cytometry, cytokine and glutamate measurements, gene expression, in situ respiration, and metabolomics. We validated our findings using a single‐nuclei RNA sequencing dataset.Results: We detected several differences in MS astrocytes including: (i) enrichment of genes associated with neurodegeneration, (ii) increased mitochondrial fission, (iii) increased production of superoxide and MS‐related proinflammatory chemokines, (iv) impaired uptake and enhanced release of glutamate, (v) increased electron transport capacity and proton leak, in line with the increased oxidative stress, and (vi) a distinct metabolic profile, with a deficiency in amino acid catabolism and increased sphingolipid metabolism, which have already been linked to MS.Interpretation: Here we describe the metabolic profile of iPSC‐derived astrocytes from PwMS and validate this model as a very powerful tool to study disease mechanisms and to perform non‐invasive drug targeting assays in vitro. Our findings recapitulate several disease features described in patients and provide new mechanistic insights into the metabolic rewiring of astrocytes in MS, which could be targeted in future therapeutic studies. ANN NEUROL 2022;91:652–669

1 January 2020 in Brazilian Journal of Analytical Chemistry
Verified
Journal Article
Closed access
ESEmerson A. F. Santos
Emerson A. F. Santos
ECElisa C. S. Cruz
Elisa C. S. Cruz
HRHenrique C. Ribeiro
Henrique C. Ribeiro
LBLuidy D. Barbosa
Luidy D. Barbosa
FZFlávia S Zandonadi
Flávia S Zandonadi
Alessandra SussuliniAlessandra Sussulini
Alessandra Sussulini

28 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
BGBruno Ghirotto
Bruno Ghirotto
DODanyllo F. Oliveira
Danyllo F. Oliveira
MCMarcella Cipelli
Marcella Cipelli
PBPaulo J. Basso
Paulo J. Basso
JLJean de Lima
Jean de Lima
NCNiels Olsen Saraiva Camara
Niels Olsen Saraiva Camara
Objective: Astrocytes play a significant role in the pathology of Multiple Sclerosis (MS). Nevertheless, for ethical reasons, most of the studies in these cells were performed on the Experimental Autoimmune Encephalomyelitis model. As there are significant differences between human and mouse cells, we aimed here to better characterize astrocytes from patients with MS (PwMS), focusing mainly on mitochondrial function and cell metabolism. Methods: We obtained and characterized induced pluripotent stem cell (iPSC)-derived astrocytes from three PwMS and three unaffected controls and performed functional assays including electron microscopy, flow cytometry, cytokine measurement, gene expression, in situ respiration, and metabolomics. Results: We detected several differences in MS astrocytes including: (i) enrichment of genes associated with mitophagy and neurodegeneration, (ii) increased mitochondrial fission and decreased mitochondrial to nuclear DNA ratio, indicating disruption of mitochondrial content, (iii) increased production of superoxide and MS-related proinflammatory chemokines, (iv) increased electron transport capacity and proton leak, in line with the increased oxidative stress, and (v) a distinct metabolic profile, with a deficiency in amino acid catabolism and increased sphingolipid metabolism, which have already been linked to MS. Interpretation: To our knowledge, this is the first study thoroughly describing the metabolic profile of iPSC-derived astrocytes from PwMS, and validating this model as a powerful tool to study disease mechanisms and to perform non-invasive drug targeting assays in vitro . Our findings recapitulate several disease features described in patients and provide new mechanistic insights into the metabolic rewiring of astrocytes in MS, which could be targeted in future therapeutic studies.

8 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
HRHenrique C. Ribeiro
Henrique C. Ribeiro
Alex DickensAlex Dickens
Alex Dickens
DDDaniel Duberg
Daniel Duberg
Jussi PostiJussi Posti
Jussi Posti
AMAndrew I. R. Maas
Andrew I. R. Maas
INInvestigators
Investigators
Patients presenting with a Glasgow Coma Scale (GCS) score of 13–15, conventionally labelled mild traumatic brain injury (mTBI), account for most hospital-presenting TBI; a substantial proportion have not recovered to pre-injury health at six months, fewer than one in ten receives structured follow-up, and at presentation they are largely indistinguishable from those who recover. Prognostic models based on clinical variables discriminate poorly here, and established protein biomarkers add little. Lipidomics reflects membrane turnover and repair rather than injury magnitude, offering a potentially complementary perspective. Blood collected within 24 h of injury from 929 patients with mTBI in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) cohort was processed to serum and analysed by Ultra-high performance liquid chromatography – Quadrupole-Time-of-flight mass spectrometry (UHPLC-QTOF). After quality-control, 278 lipid features were retained and clustered by Gaussian mixture modelling. Associations between lipid features, six protein biomarkers, Corticosteroid Randomisation After Significant Head injury (CRASH) clinical variables and 6-month Glasgow Outcome Scale–Extended (GOSE) outcome were assessed by Spearman correlation and Jonckheere–Terpstra trend tests. Variables were selected by ordinal elastic-net and modelled by proportional odds logistic regression, comparing CRASH-only with CRASH-plus-marker models, built in a development set (n = 411 with complete covariates) and assessed in a test set (n = 367). Lipid clusters rich in lysophosphatidylcholines (LPCs), sphingomyelins/ceramides and ether-linked phosphatidylcholines (PC-O) correlated positively with favourable outcome and inversely with the injury proteins. Summed choline-containing lipid intensity rose across GOSE (p < 0.0001). Elastic-net selected three proteins (GFAP, NfL, S100B) and seven lipid features, three annotated (LPC(18:2), LPC(20:5), PC(O-34:3)). Adding lipids and proteins increased the area under the receiver operating characteristic curve (AUC) at every threshold, reaching nominal significance at GOSE ≥ 7 (AUC 0.728, 95% CI 0.671–0.785, p = 0.022), not surviving correction for four comparisons. The averaged c-index rose from 0.720 to 0.751 and Nagelkerke R 2 from 0.125 to 0.242. The three proteins and three annotated lipids showed opposing trends across GOSE (all p < 0.001). The acute serum lipidome is associated with 6-month functional outcome after mTBI. LPCs and PC-Os moved opposite to the injury proteins and may index membrane repair rather than injury burden, offering pathophysiological insight and possible therapeutic targets. Adding them to clinical variables gave modest gains, greatest at the upper end of the outcome scale, where existing models perform worse. The gain is small and exploratory; replication with targeted assays is needed first.